John Gilleran

505 total citations
15 papers, 400 citations indexed

About

John Gilleran is a scholar working on Molecular Biology, Oncology and Nutrition and Dietetics. According to data from OpenAlex, John Gilleran has authored 15 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Nutrition and Dietetics. Recurrent topics in John Gilleran's work include Trace Elements in Health (7 papers), Cancer-related Molecular Pathways (4 papers) and MicroRNA in disease regulation (3 papers). John Gilleran is often cited by papers focused on Trace Elements in Health (7 papers), Cancer-related Molecular Pathways (4 papers) and MicroRNA in disease regulation (3 papers). John Gilleran collaborates with scholars based in United States, Netherlands and Canada. John Gilleran's co-authors include S. David Kimball, Darren R. Carpizo, Xin Yu, Stewart N. Loh, Adam R. Blanden, Madeleine M. Joullié, John Langenfeld, David J. Augeri, Bing Na and Elaine Langenfeld and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Clinical Cancer Research.

In The Last Decade

John Gilleran

15 papers receiving 397 citations

Peers

Countries citing papers authored by John Gilleran

Since Specialization

Citations

This map shows the geographic impact of John Gilleran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Gilleran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Gilleran more than expected).

Fields of papers citing papers by John Gilleran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Gilleran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Gilleran. The network helps show where John Gilleran may publish in the future.

Co-authorship network of co-authors of John Gilleran

This figure shows the co-authorship network connecting the top 25 collaborators of John Gilleran. A scholar is included among the top collaborators of John Gilleran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Gilleran. John Gilleran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Structure–Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials 2024 ·Journal of Medicinal Chemistry ·John Gilleran, (unknown), (unknown), (unknown), (unknown), Edward B. Miller, Ashley Hutchinson, Aiping Dong, Alma Seitova, (unknown), David J. Augeri, Levon Halabelian, John J. Siekierka, David P. Rotella, John Gordon, Wayne E. Childers, Mark C. Grier, Bart L. Staker, Jacques Y. Roberge, Purnima Bhanot	3
2	Bone morphogenetic protein signaling regulation of AMPK and PI3K in lung cancer cells and C. elegans 2022 ·Cell & Bioscience ·Mehul Vora, Arindam Mondal, Dongxuan Jia, (unknown), (unknown), John Gilleran, Jacques Y. Roberge, Christopher Rongo, John Langenfeld	7
3	Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells 2022 ·Cell Communication and Signaling ·Arindam Mondal, Jacques Y. Roberge, John Gilleran, Youyi Peng, Dongxuan Jia, (unknown), Yash Patel, (unknown), (unknown), John Langenfeld	9
4	Identification of Dihydromyricetin and Metabolites in Serum and Brain Associated with Acute Anti-Ethanol Intoxicating Effects in Mice 2021 ·International Journal of Molecular Sciences ·(unknown), (unknown), Joshua Silva, Daryl L. Davies, Bo Yuan, Qingli Wu, (unknown), (unknown), John Gilleran, Lihong Hao, Jacques Y. Roberge, Nicholas T. Bello, James E. Simon	11
5	Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells 2021 ·Cell Communication and Signaling ·Arindam Mondal, (unknown), Mehul Vora, (unknown), (unknown), Elaine Langenfeld, Dongxuan Jia, Youyi Peng, John Gilleran, Jacques Y. Roberge, Christopher Rongo, Salma K. Jabbour, John Langenfeld	9
6	Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53 2021 ·Journal of Medicinal Chemistry ·John Gilleran, Xin Yu, (unknown), (unknown), Bing Na, David J. Augeri, Adam R. Blanden, S. David Kimball, Stewart N. Loh, Jacques Y. Roberge, Darren R. Carpizo	24
7	Abstract 3432: Zinc metallochaperones for mutant p53 reactivation in cancer therapeutics 2020 ·Cancer Research ·Xin Yu, Bing Na, Saif Zaman, (unknown), John Gilleran, (unknown), (unknown), Adam R. Blanden, Yue Liu, David A. Boothman, Stewart N. Loh, S. David Kimball, Shridar Ganesan, Darren R. Carpizo	2
8	Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding 2019 ·Molecular Cancer Therapeutics ·Saif Zaman, Xin Yu, (unknown), Adam R. Blanden, Yue Liu, (unknown), Bing Na, (unknown), John Gilleran, David A. Boothman, Stewart N. Loh, S. David Kimball, Darren R. Carpizo	25
9	Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation 2019 ·npj Breast Cancer ·Bing Na, Xin Yu, (unknown), John Gilleran, Ming Yao, Tzeh Keong Foo, Chunxia Chen, Dirk F. Moore, Yong Lin, S. David Kimball, Bing Xia, Shridar Ganesan, Darren R. Carpizo	47
10	Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics 2018 ·Clinical Cancer Research ·Xin Yu, Samuel Kogan, Ying Chen, (unknown), (unknown), Hongxia Lin, John Gilleran, Brian Buckley, Dirk F. Moore, Joseph Bertino, Chang Chan, S. David Kimball, Stewart N. Loh, Darren R. Carpizo	33
11	Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma 2017 ·Targeted Oncology ·Monica Bartucci, Mohamed S. Hussein, (unknown), (unknown), Michele Patrizii, Saurabh V. Laddha, (unknown), (unknown), John Gilleran, (unknown), (unknown), S. David Kimball, David J. Augeri, Hatem E. Sabaawy	19
12	Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53 2017 ·Molecular Pharmacology ·Xin Yu, Adam R. Blanden, (unknown), Saif Zaman, Yue Liu, John Gilleran, (unknown), S. David Kimball, Stewart N. Loh, Darren R. Carpizo	45
13	Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death 2016 ·Molecular Cancer ·(unknown), Elaine Langenfeld, (unknown), John Gilleran, John Langenfeld	37
14	Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore 2015 ·Molecular Pharmacology ·Adam R. Blanden, Xin Yu, Aaron J. Wolfe, John Gilleran, David J. Augeri, Ryan S. O’Dell, Eric C. Olson, S. David Kimball, Thomas J. Emge, Liviu Movileanu, Darren R. Carpizo, Stewart N. Loh	69
15	A Regio- and Stereoselective Approach to Quaternary Centers from Chiral Trisubstituted Aziridines 2007 ·Journal of the American Chemical Society ·(unknown), (unknown), John Gilleran, (unknown), Madeleine M. Joullié	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact